Key Highlights

  • Xencor shares were trading up 10.95% at $34.00, against a prior close of $30.64.
  • XmAb819 showed a 45.5% confirmed response rate at the 400 mcg/kg dose.
  • The company plans a global randomized study against tivozanib.
  • Truist, Wells Fargo and RBC raised price targets to $40, $44 and $43.
  • Third-quarter results are due November 9.

XmAb819 Data and Analyst Upgrades Drive the Move

Xencor (NASDAQ:XNCR) shares were trading up 10.95% at $34.00 on Wednesday, close to a 52-week high of $34.48. Updated Phase 1 data for XmAb819, an ENPP3 by CD3 bispecific T-cell engager, are in focus, and analysts have raised targets. A broad rally in health stocks after the midterms also helped.

Truist lifted its target to $40, Wells Fargo to $44 and RBC to $43.

Strong Responses in Advanced Kidney Cancer

The 400 mcg/kg dose was chosen as the proposed recommended dose based on a 45.5% confirmed response rate, a 55% unconfirmed response rate and an 82% six-month progression-free survival estimate in advanced clear cell renal cell carcinoma. The patients were heavily pretreated.

Xencor plans to discuss a potential Accelerated Approval path with the FDA in the first half of 2027 and to start a global randomized study of XmAb819 against tivozanib in patients who have progressed after checkpoint and VEGF-targeted therapy.

A Partnership-Driven Business With Heavy Losses

Xencor uses its XmAb protein engineering platform to build antibody and cytokine therapies, advancing a wholly owned pipeline that includes XmAb819, plamotamab and vudalimab. It also licenses its technology to partners and earns fees, milestones and royalties from marketed medicines. The company is unprofitable, and Revenue is uneven.

Overbought Signals Ahead of Earnings

Technical indicators show the stock as overbought after the run, and third-quarter results are due November 9. The 52-week range runs from $10.38 to $34.48, so the shares have more than tripled from their low. A phase 3 plan is encouraging, but registration studies take years and carry risk.